Regencell Bioscience (NASDAQ:RGC) Trading Down 7.8% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) fell 7.8% during trading on Monday . The company traded as low as $5.82 and last traded at $5.8750. 454,068 shares changed hands during mid-day trading, an increase of 46% from the average daily volume of 311,824 shares. The stock had previously closed at $6.37.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Regencell Bioscience currently has a consensus rating of “Sell”.

Regencell Bioscience Trading Down 8.0%

The stock’s fifty day moving average price is $20.90 and its 200-day moving average price is $25.25.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in shares of Regencell Bioscience during the 2nd quarter valued at about $1,701,000. BNP Paribas Financial Markets bought a new stake in Regencell Bioscience in the second quarter worth approximately $768,000. XTX Topco Ltd acquired a new position in shares of Regencell Bioscience during the 3rd quarter worth $598,000. Vident Advisory LLC raised its holdings in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after acquiring an additional 17,143 shares in the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.